The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The importance of predicting venetoclax response in patients with AML
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses why predicting venetoclax response in patients with acute myeloid leukemia (AML) remains a challenge in the field, and further outlines some genomic-related hypotheses as to why some patients may not respond to this agent. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
